Rivaroxaban ‘beneficial’ after revascularisation for claudication

Further results from the VOYAGER-PAD trial show use of the agent reduces major cardiovascular events
senior man walking with 2 canes

Patients who undergo lower extremity revascularisation for claudication and then have rivaroxaban have fewer major cardiovascular events than if they take placebo, researchers report.

The results come from a post-hoc sub-analysis of the VOYAGER-PAD trial, looking just at data for 5031 patients who had their revascularisation procedure for claudication.